EA032054B1 - Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления - Google Patents

Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления Download PDF

Info

Publication number
EA032054B1
EA032054B1 EA201301029A EA201301029A EA032054B1 EA 032054 B1 EA032054 B1 EA 032054B1 EA 201301029 A EA201301029 A EA 201301029A EA 201301029 A EA201301029 A EA 201301029A EA 032054 B1 EA032054 B1 EA 032054B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
amyloid
disease
antibodies
antigen
Prior art date
Application number
EA201301029A
Other languages
English (en)
Russian (ru)
Other versions
EA201301029A1 (ru
Inventor
Мартин Клайншмидт
Штефан Шиллинг
Йенс-Ульрих Рафельд
Ханс-Ульрих Демут
Кристин Эберманн
Original Assignee
Пробиодруг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пробиодруг Аг filed Critical Пробиодруг Аг
Publication of EA201301029A1 publication Critical patent/EA201301029A1/ru
Publication of EA032054B1 publication Critical patent/EA032054B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
EA201301029A 2011-03-16 2012-03-16 Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления EA032054B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453449P 2011-03-16 2011-03-16
PCT/EP2012/054629 WO2012123562A1 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
EA201301029A1 EA201301029A1 (ru) 2014-05-30
EA032054B1 true EA032054B1 (ru) 2019-04-30

Family

ID=45833428

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301029A EA032054B1 (ru) 2011-03-16 2012-03-16 Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления

Country Status (15)

Country Link
US (2) US8809508B2 (https=)
EP (1) EP2686346B1 (https=)
JP (1) JP6220675B2 (https=)
KR (1) KR102020072B1 (https=)
CN (1) CN103459421B (https=)
AU (1) AU2012228236B2 (https=)
BR (1) BR112013023211B1 (https=)
CA (1) CA2828433C (https=)
DK (1) DK2686346T3 (https=)
EA (1) EA032054B1 (https=)
IL (1) IL227847A0 (https=)
MX (1) MX343873B (https=)
SG (1) SG192805A1 (https=)
WO (1) WO2012123562A1 (https=)
ZA (1) ZA201305946B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512115B2 (en) 2013-03-15 2016-12-06 Probiodrug Ag Inhibitors
WO2016097305A1 (en) 2014-12-19 2016-06-23 Probiodrug Ag Novel method for the detection of pglu-abeta peptides
US10494425B2 (en) * 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
IL256579B2 (en) * 2015-07-16 2023-03-01 Probiodrug Ag Human antibodies
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
US20210096128A1 (en) * 2019-10-01 2021-04-01 Repligen Corporation Determination of protein concentration in a fluid
KR102790945B1 (ko) * 2022-09-23 2025-04-04 경성대학교 산학협력단 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트
CN121253823A (zh) * 2025-10-10 2026-01-02 山东九嘉生物科技有限公司 一种用于检测胃蛋白酶原ⅰ的化学发光试剂盒及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149485A2 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating amyloidoses
US20100021478A1 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
ES2275570T3 (es) * 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. Peptidos amiloides beta quimericos.
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
US20100028351A1 (en) 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5599614B2 (ja) 2006-11-09 2014-10-01 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
EP2091945B1 (en) 2006-11-09 2014-01-15 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
WO2008128983A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
JP5675340B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー 新規阻害剤
JP5675343B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP5676249B2 (ja) 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
EP2211886A4 (en) * 2007-10-15 2011-07-27 Centocor Ortho Biotech Inc HUMAN ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, PROCESSES AND APPLICATIONS
PT2448968T (pt) * 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149485A2 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating amyloidoses
US20100021478A1 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIETMAR RUDOLF THAL ; ESTIBALIZ CAPETILLO-ZARATE ; CHRISTIAN SCHULTZ ; UDO R�B ; TAKAOMI C. SAIDO ; HARUYASU YAMAGUCHI ; CHRISTIAN: "Apolipoprotein E co-localizes with newly formed amyloid β-protein (Aβ) deposits lacking immunoreactivity against N-terminal epitopes of Aβ in a genotype-dependent manner", ACTA NEUROPATHOLOGICA ;, SPRINGER, BERLIN, DE, vol. 110, no. 5, 1 November 2005 (2005-11-01), Berlin, DE, pages 459 - 471, XP019340810, ISSN: 1432-0533, DOI: 10.1007/s00401-005-1053-1 *
IWATSUBO T, ET AL.: "FULL-LENGTH AMYLOID-BETA(1-42(43)) AND AMINO-TERMINALLY MODIFIED AND TRUNCATED AMYLOID-BETA42(43) DEPOSIT IN DIFFUSE PLAQUES", AMERICAN JOURNAL OF PATHOLOGY., ELSEVIER INC., US, vol. 149, no. 06, 1 December 1996 (1996-12-01), US, pages 1823 - 1830, XP009008612, ISSN: 0002-9440 *
KANGNING LIU ; INGRID SOLANO ; DAVID MANN ; CYNTHIA LEMERE ; MARC MERCKEN ; JOHN Q. TROJANOWSKI ; VIRGINIA M.-Y. LEE: "Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease", ACTA NEUROPATHOLOGICA ;, SPRINGER, BERLIN, DE, vol. 112, no. 2, 1 June 2006 (2006-06-01), Berlin, DE, pages 163 - 174, XP019426174, ISSN: 1432-0533, DOI: 10.1007/s00401-006-0077-5 *
SAITO TAKANOMI C ET AL: "Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain.", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 215, no. 3, 1 January 1996 (1996-01-01), AMSTERDAM, NL, pages 173 - 176, XP002236342, ISSN: 0304-3940, DOI: 10.1016/0304-3940(96)12970-0 *

Also Published As

Publication number Publication date
EP2686346B1 (en) 2016-12-14
BR112013023211B1 (pt) 2022-11-08
NZ614217A (en) 2015-12-24
AU2012228236A1 (en) 2013-10-03
IL227847A0 (en) 2013-09-30
WO2012123562A1 (en) 2012-09-20
JP6220675B2 (ja) 2017-11-01
SG192805A1 (en) 2013-09-30
US9657089B2 (en) 2017-05-23
KR102020072B1 (ko) 2019-11-04
US20140255414A1 (en) 2014-09-11
CN103459421B (zh) 2017-07-14
MX2013010571A (es) 2013-12-02
US8809508B2 (en) 2014-08-19
KR20140006019A (ko) 2014-01-15
MX343873B (es) 2016-11-25
CN103459421A (zh) 2013-12-18
US20120237529A1 (en) 2012-09-20
BR112013023211A2 (pt) 2016-11-22
CA2828433A1 (en) 2012-09-20
AU2012228236B2 (en) 2016-10-27
JP2014509860A (ja) 2014-04-24
EA201301029A1 (ru) 2014-05-30
DK2686346T3 (en) 2017-03-27
CA2828433C (en) 2020-08-04
EP2686346A1 (en) 2014-01-22
ZA201305946B (en) 2014-10-29

Similar Documents

Publication Publication Date Title
CN102131519B (zh) 诊断抗体测定
EA032054B1 (ru) Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления
HK1192568B (en) Diagnostic antibody assay
HK1192568A (en) Diagnostic antibody assay
NZ614217B2 (en) Diagnostic antibody assay
HK1158946B (en) Diagnostic antibody assay

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TM

TC4A Change in name of a patent proprietor in a eurasian patent
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title